It Takes Multiple to Mambo

Why It Matters

Multivalent molecules demonstrate that strategic dimerization or oligomerization can dramatically enhance potency, selectivity, and pharmacokinetic profiles, expanding the viable chemical space for oral therapeutics. This paradigm shift promises broader therapeutic options across oncology, cardiovascular disease, and proteostasis targeting.

Key Takeaways

• Dimeric linkers boost BET selectivity >30‑fold
• Muvalaplin dimer improves Lp(a) inhibition 10,000‑fold
• MRT‑31619 forms 1,500 Ų CRBN homodimer, avoids hook effect
• VHL pseudodimer CC124 creates long‑lived inactive ternary complex
• Multivalency expands bRo5 oral drug possibilities

Pulse Analysis

The drug discovery community is increasingly embracing multimeric chemistry to navigate the bRo5 landscape, where traditional small‑molecule rules often limit oral bioavailability. By linking two or more pharmacophores, researchers can simultaneously engage multiple binding sites, increase residence time, and improve physicochemical properties that favor gut absorption. This approach leverages the concept of avidity, turning modest monomeric affinities into high‑impact therapeutic interactions without sacrificing drug‑like characteristics.

Case studies underscore the practical power of this strategy. GSK’s GSK785 demonstrates how precise linker geometry can dictate isoform selectivity within the BET family, delivering a 30‑fold preference for BRD4 over BRD3. Eli Lilly’s muvalaplin series shows that dimerizing a hit against apo(a) yields a staggering 10,000‑fold enhancement in Lp(a) inhibition, with a trimeric version adding a further two‑fold gain. These potency leaps arise from multivalent binding to the repetitive Kringle IV domains, highlighting how structural redundancy in targets can be exploited for therapeutic advantage.

In the realm of targeted protein degradation, multivalency is redefining molecular glue design. MRT‑31619 induces a 1,500 Ų CRBN homodimer interface, achieving cooperative degradation without the typical hook effect that plagues heterobifunctional degraders. Similarly, the VHL‑directed pseudodimer CC124 forms a stable, trans‑ubiquitination‑incompetent complex that prolongs HIF pathway activation while avoiding compensatory VHL up‑regulation. These examples illustrate that dimerization can fine‑tune degradation kinetics and selectivity, opening new avenues for modulating proteostasis. As the field matures, multimeric scaffolds are poised to become a mainstay in oral drug pipelines, offering a versatile toolkit for tackling previously intractable targets.